Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | AOC2 | O75106 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5120304 | 1.00 | TAAR1 (0.39) | TAAR1KIF11ALDH1A1DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL4730956 | 0.98 | SMN1; SMN2 (0.39) | TAAR1KIF11ALDH1A1DRD2DRD4 | |
| SCHEMBL5481115 | 0.80 | ALDH1A1 (0.54) | ALDH1A1KDM4ETDP1 | |
| SCHEMBL6563061 | 0.80 | TAAR1 (0.36) | TAAR1KIF11SMN1; SMN2KDM4ETDP1 | |
| SCHEMBL5527328 | 0.80 | TAAR1 (0.44) | TAAR1KIF11SMN1; SMN2KMT2AKCNH2 | |
| Hydrochloric Acid SCHEMBL654753 | 0.79 | SMN1; SMN2 (0.36) | TAAR1KIF11SMN1; SMN2KDM4ETDP1 | |
| SCHEMBL5533209 | 0.77 | KIF11 (0.49) | TAAR1KIF11DRD2DRD4SMN1; SMN2 | |
| SCHEMBL5288256 | 0.75 | SCN4A (0.37) | KIF11ALDH1A1NOTUMSCN4ASMN1; SMN2 | |
| SCHEMBL5530178 | 0.74 | KIF11 (0.49) | KIF11ALDH1A1DRD2DRD4HTT | |
| SCHEMBL9707204 | 0.73 | MAPK1 (0.52) | TAAR1ALDH1A1DRD2DRD4NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569729-B2 | Analyzing stability of atomoxetine hydrochloride by determining pH of sample of atomoxetine hydrochloride in aqueous solution; stable atomoxetine hydrochloride contains reduced amount of free hydrogen chloride, such that an aqueous solution has a pH of 4-7; shelf life, purity; attention-deficit disorder | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2009-08-04 | — | — | US | disclosed |
| US-20080146675-A1 | Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability | CASTELLI EUGENIO | 2008-06-19 | — | — | US | disclosed |
| EP-1889828-A1 | Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-02-20 | — | — | EP | disclosed |
| EP-1751085-A1 | STABLE ATOMOXETINE HYDROCHLORIDE, A PROCESS FOR THE PREPARATION THEREOF, AND AN ANALYTICAL CONTROL OF ITS STABILITY | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2007-02-14 | — | — | EP | disclosed |
| US-20060252836-A1 | Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability | TEVA PHARMACEUTICALS USA, INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006108120-A1 | STABLE ATOMOXETINE HYDROCHLORIDE, A PROCESS FOR THE PREPARATION THEREOF, AND AN ANALYTICAL CONTROL OF ITS STABILITY | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252836-A1 | Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability | SLC6A4, SLC6A2, HTR5A | TAAR1 99/4885KIF11 1023/4885ALDH1A1 1302/4885 |
| US-20080146675-A1 | Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability | SLC6A4, SLC6A2, HTR5A | TAAR1 99/4885KIF11 1023/4885ALDH1A1 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.